WhitePaperPharmaR&DAnnualReview2024Lookbackatkeypipelinetrendsfromthelast12monthssoyoucanforecastsuccessin2024ContentsWelcome03Introduction:TotalPipelineSize05PleasantoutlookforpharmaasthingscontinuetoheatupDevelopingSystems:The2024PipelinebyPhase08ClinicaldevelopmentadvancesstillfaceastiffheadwindTopCompanies11Someenjoyamomentinthesun,butforothersthefuturelooksmorehazyTherapiesandDiseases19CancerstilltakingR&DbystormRegionalVariations31WheretheoutlookseemstobebrightestMechanismsandTargets54Immuno-oncologymakeshaywhilethesunshinesTypesofPipelineDrugs59Isthecontinuedmoveintobiotechstartingtomeetafrostyreception?What’stheForecastforPharma?62Plentyofraysofs...
发表评论取消回复